The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.

Ionis Pharmaceuticals and Johnson & Johnson Innovation – JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA conjugate medicines.

The Alphabet, GSK, WuXi AppTec, Johnson & Johnson, Roche and Illumina-backed genetic testing service has now raised over $870m altogether.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Today’s deal net round ups the smaller investments from across the university innovation ecosystem that have occurred over the holiday period.

Lilly Asia Ventures achieved an exit in a Hong Kong offering in which the oncology therapy developer floated at the top of its range.

Legend Star and CMB International are among the participants in the cancer drug developer’s latest round, which was led by Tsing Song Capital.

Tencent Investment was among the participants in late-stage round for the online medical information and social networking service.

Lilly Asia Ventures has put more funding into Transcenta to help sustain the antibody drug developer's clinical-stage pipeline.